Connect with us

Medicinal

UK’s NCRI endorses research into cannabis for treating cancer pain

The development will give hope to cancer patients as current treatment options for cancer-related pain are largely ineffective.

Published

on

UK’s NCRI endorses research into cannabis for treating cancer pain

UK-based CBD Science Group has received an endorsement from the National Cancer Research Institute (NCRI) for its study investigating the role of cannabis in treating cancer pain.

Biopharmaceutical company CBD Science Group has received an endorsement from the NCRI, which has seen its NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse CBD Science’s Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer-related pain.

There are currently an estimated three million patients in the UK suffering from cancer, 39.3% of which are affected by pain following curative treatment; 55% affected by pain during anticancer treatment; and 66.4% in advanced, metastatic, or terminal disease.

An alternative treatment for pain

CBD Science Group is carrying out the peer-reviewed clinical trial which aims to deliver approved therapies to patients nationally at a rapid pace.

CCO of CBD Science, Graeme McFarlane, said: “We are delighted and proud to have been offered this endorsement from the NCRI LWBC, which offers hope to millions of people with long term cancer pain around the world. 

“This partnership will further progress CBD Science Group towards our objective of realising the advantages of cannabinoids in fulfilling this urgent need of suffering patients. We strongly believe in the opportunity that our RWE study presents, and look forward to working closely and deepening our relationship with the NCRI.”

The NICE guidelines for medical cannabis found that evidence is lacking for chronic pain associated with cancer patients, which CBD Science says renders research into the use of cannabinoids as an alternative medicine timely.

Read more: Breast cancer breakthrough for medical cannabis company Appollon Formularies

Co-chair of NCRI Living With and Beyond Cancer Research Group, professor Emeritus Sam Ahmedzai, commented: “Previous research into cancer-related pain focused on those with advanced disease, however, there is a large and rapidly growing population of people surviving for many years with cancer. 

“The reality is that chronic pain related to the cancer itself or indeed arising from the anti-cancer treatments, is an insurmountable barrier to living a productive and rewarding life with family and friends – at all stages of cancer. 

“Sadly current pain treatment options are largely ineffective or cause even more harmful side-effects; therefore new research is urgently needed to find better therapies. I am delighted to actively participate in CBD Science Group’s goal of finding an effective and safer medicinal cannabis solution to relieve the suffering of patients living with cancer-related pain.”

Medicinal

Khiron announces opening of first Zerenia medical cannabis clinic in Brazil

The new clinic will increase patient access to medical cannabis.

Published

on

Khiron announces opening of first Zerenia medical cannabis clinic in Brazil
Home » News » Medicinal » UK’s NCRI endorses research into cannabis for treating cancer pain

European medical cannabis group, Khiron, has opened its first Zerenia medical cannabis clinic in Ipanema in Rio de Janeiro, Brazil, as it continues its expansion into the country.

As part of its expansion into a number of jurisdictions across the globe, including Germany and Spain following recent developments, Khiron has now opened its Zerenia Rio clinic.

The clinic will provide physical consultations and telehealth services, connecting patients with medical specialists trained in the ethical, safe and responsible prescription of cannabinoid-based medications.

Read more: Khiron gains German distribution capabilities with new acquisition

The medications focus on the treatment of conditions such as chronic pain, neurological pathologies, palliative care, rheumatology, psychiatry, geriatrics, endocrinology, gastroenterology, gynecology, otorhinolaryngology and dermatology.

Located in Ipanema, a city with more than 12 million people, the clinic’s initial phase will have a total capacity of approximately 23,000 patient consults per year.

The clinic will be under the leadership of Dr Eduardo Faveret as medical director and will open with more than 13 doctors for both in-person and telehealth models.

Read more: Khiron continues expansion into Spain after medical bill green light

Dr Faveret commented: “Brazil continues to experience exponential growth in prescribing doctors and demand for medical cannabis products by patients. Zerenia Rio, is positioned as a comprehensive and humanised pioneer in patient health service and prevention to improve the quality of life of Brazilian families.

“We have assembled a multidisciplinary medical team that covers diverse medical cannabis specialties and treatments, which makes our Zerenia Rio clinic unique in Brazil.”

Dr Faveret and the Zerenia Rio clinic will be supported by Khiron’s strategic alliances with doctors and patient associations, including CANNAB in Salvador de Bahia, and leading medical distributors such as TAIMIN in Rio de Janeiro and Sao Paulo.

Later this year, Khiron is expecting to launch additional THC medical cannabis products in the country, which will complement its current global portfolio.

CEO and director of Khiron Life Sciences, Alvaro Torres, said: “Khiron has developed a unique, successful, and sustainable model with the implementation of Zerenia in Colombia, Perú, and the United Kingdom.

“Brazil is Latin America´s largest addressable market with more than 210 million people and we believe that our Zerenia model will replicate the success we have experienced around the world. 

“We have served more than 25,000 individual patients across the globe through our model, with high peer patient acquisition and retention rates. We have a fantastic team on the ground in Brazil composed of doctors, nurses, patient advocates, and administrative staff in our Zerenia™ Rio clinic that will elevate our patient-first model to new levels. 

“Khiron’s Zerenia Rio clinic in Brazil will also allow us to continue to generate more patient-based evidence on the pharmacoeconomic benefits of our Khiron-branded medical cannabis products, and through this data, Khiron could eventually be able to provide insurance benefits for patients as we have done in Colombia.”

Continue Reading

Medicinal

Akanda and Cansativa to supply German patients with cannabis flower

The collaboration will see patients have access to two novel cultivars.

Published

on

Akanda and Cansativa to supply German patients cannabis flower
Home » News » Medicinal » UK’s NCRI endorses research into cannabis for treating cancer pain

Akanda Corp and Cansativa are collaborating to supply the German market with dried flowers from Akanda’s EU-GMP certified indoor grow facility in Sintra, Portugal.

Under the collaboration, Akanda is expected to deliver at least 1,000 kg of flower to Cansativa over the first 12 months of the agreement.

All pharmacies in Germany will be able to purchase the products through the Cansativa platform. Since the award of the Federal Institute for Drugs and Medical Devices (BfArM) in August 2020, Cansativa Group is the only company with approval for the distribution of medical cannabis from German cultivation. 

Read more: Akanda to supply cannabis for FDA trials of potential multi-million dollar medicine

Co-founder and CEO of the Cansativa Group, Benedikt Sons, commented: “We are very glad about this agreement that allows us to introduce two novel medical cannabis flowers to the German market. 

“This enables patient access to an additional supplier with a new and innovative range of medical products. This exciting cooperation marks another step in improving the product diversity and security of supply on the German market. 

Read more: Akanda to contest liquidation of its Lesotho-based subsidiary

“We look forward to a long-term relationship with Akanda, with whom we share an important part of our mission: We want to enable physicians, pharmacies, and patients by giving them access to an extensive medical product portfolio and help improve the quality of life with the help of medical cannabis.”

CEO of Akanda, Tej Virk, added: “Our prized purpose-built indoor grow facility is the only one of its kind in Portugal that can produce EU-GMP medical cannabis equivalent to the adult-use grades available in North America. 

“It has both the quality and scalability to meet the growing demand for medical cannabis in fast-growing markets across the EMEA region, such as Germany. 

“We are equally excited to be partnering with the Cansativa Group to bring some of our best strains to Germany through their platform. This supply agreement represents one of the largest agreements in the nascent European medical cannabis industry and is certainly Akanda’s most substantial commercial development to date, enabling new patient experience.”

Continue Reading

Medicinal

Khiron gains German distribution capabilities with new acquisition

Khiron Life Sciences has completed the acquisition of Pharmadrug Production GmbH.

Published

on

Khiron gains German distribution capabilities with new acquisition
Home » News » Medicinal » UK’s NCRI endorses research into cannabis for treating cancer pain

Through its acquisition of Pharmadrug Production,  Khiron will have access to EU-GMP manufacturing capabilities and a distribution hub for medical cannabis.

Khiron has stated that the acquisition of Pharmadrug Production will provide the company with direct access to German pharmacies and increase in gross margins for its products. 

It will also allow Khiron to accelerate the expansion of its medical product portfolio with additional exclusive flower varieties and a THC‑dominant full spectrum extract that combines the medicinal properties and areas of application of the established THC isolate formulations (dronabinol) with the specific advantages of a full-spectrum extract.

Read more: Khiron continues expansion into Spain after medical bill green light

President of Khiron Europe, Franziska Katterbach, stated: “We are very pleased that we have now received all the necessary permits and licenses in connection with the acquisition and integration of Pharmadrug Production and that we can continue our growth course in Europe on an expedited pace with full control over the value chain up to the pharmacy. We are very excited to take advantage of the Pharmadrug Production’s excellent infrastructure and experienced team, which will enrich us professional and personally. 

“After opening our Zerenia clinic in London last year and now adding a powerful asset in Germany, our European force is complete and ready to ramp our sales in Germany. 

“Now we expect to sell our products faster and at higher margins directly to German pharmacies, which will save distribution fees. A first signal in this direction is the imminent expansion of our medical portfolio for European patients. 

“These are products manufactured exclusively in Europe, and our medical portfolio now covers the entire spectrum of chemotypes and forms of administration. We will provide more detailed information on our new products in a timely manner.”

The development is in line with the Khiron’s strategy to strengthen its foothold in Europe, having also recently welcomed Spain’s progression on the regulation of medical cannabis, stating it is looking forward to bringing its clinical expertise and evidence from Khiron-owned Zerenia Clinics to Spanish patients.

Khiron, which recently reported a record 2022 Q1 with revenue of $4.6m, has stated that additional new products are already in the pipeline, that will comprise the entire spectrum of therapies with medical cannabis to be able to offer the right therapy for every patient.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]